Mach42 is delivering the next step-change in simulation acceleration, leveraging state-of-the-art machine learning and artificial intelligence technology to simplify, automate, and accelerate simulation tasks. 

We leverage proprietary neural network technology to accelerate expensive calculations, with minimal data and high accuracy, providing many orders of magnitude speedup. 

Working at the cutting-edge of ‘Embodied Intelligence’ - the convergence of AI and robots – Oxford Dynamics vision is to produce intelligent machines able to sense, learn, and act in complex environments.  

Along this journey OD is producing generative AI products such as AVIS, an enterprise-level modular software able to process complex data using natural language.  

Founded in 2020, Oxford Dynamics brings together a unique blend of hard-won serial tech entrepreneurial expertise, cutting-edge AI and robotics. 

Sitryx is a clinical-stage biopharmaceutical company focused on modulating immune cell metabolism to advance a new generation of disease-modifying therapies for autoimmune and inflammatory diseases.

Led by a highly experienced management team and supported by world class academic founders, Sitryx was established in 2018 and has raised >$75 million to date from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Lilly and GSK.